Skip to main content
Erschienen in: Journal of Cancer Education 1/2017

04.08.2015

Prostate Cancer on the Web—Expedient Tool for Patients’ Decision-Making?

verfasst von: Hendrik Borgmann, Jan-Henning Wölm, Stefan Vallo, Rene Mager, Johannes Huber, Johannes Breyer, Johannes Salem, Stacy Loeb, Axel Haferkamp, Igor Tsaur

Erschienen in: Journal of Cancer Education | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Many patients diagnosed with cancer search for health information on the Web. We aimed to assess the quality and reliability of online health information on prostate cancer. Google, Yahoo, and Bing were searched for the term “prostate cancer.” After selecting the most frequented websites, quality was measured by DISCERN score, JAMA benchmark criteria, and presence of HONcode certification. Popularity was assessed by Alexa tool, while accessibility, usability, and reliability were investigated by LIDA tool. Readability was analyzed by Flesch-Kincaid Reading Grade Level and Automated Readability Index. All 13 selected websites were rated as being of high quality according to the DISCERN instrument (76.5 ± 2.6 out of 80 points). JAMA benchmark criteria were fulfilled by 87 % of websites, whereas only 37 % were certified by the HONcode. Median Alexa Traffic Rank was 2718 ranging from 7 to 679,038. Websites received 2.3 ± 0.5 daily pageviews per visitor and users spent an average of 2 min 58 s ± 39 sec on the website. Accessibility (92 ± 5 %) and usability (92 ± 3 %) scores were high and reliability (88 ± 8 %) moderate according to the LIDA tool. Flesch-Kincaid Grade Level was 7.9 ± 2.2, and Automated Readability Index was 7.5 ± 2.4, rating the websites as fairly difficult to read. In conclusion, quality, accessibility, and usability of websites on prostate cancer provided a high rating in the current analysis. These findings are encouraging in view of the growing frequency of patients’ access of health information online.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Diaz JA, Griffith RA, Ng JJ, Reinert SE, Friedmann PD, Moulton AW (2002) Patients’ use of the Internet for medical information. J Gen Intern Med 17(3):180–185CrossRefPubMedPubMedCentral Diaz JA, Griffith RA, Ng JJ, Reinert SE, Friedmann PD, Moulton AW (2002) Patients’ use of the Internet for medical information. J Gen Intern Med 17(3):180–185CrossRefPubMedPubMedCentral
3.
6.
Zurück zum Zitat Patel A, Cobourne MT (2014) The design and content of orthodontic practise websites in the UK is suboptimal and does not correlate with search ranking. Eur J Orthod. doi:10.1093/ejo/cju078 Patel A, Cobourne MT (2014) The design and content of orthodontic practise websites in the UK is suboptimal and does not correlate with search ranking. Eur J Orthod. doi:10.​1093/​ejo/​cju078
10.
Zurück zum Zitat Silberg WM, Lundberg GD, Musacchio RA (1997) Assessing, controlling, and assuring the quality of medical information on the Internet: Caveant lector et viewor—Let the reader and viewer beware. JAMA 277(15):1244–1245CrossRefPubMed Silberg WM, Lundberg GD, Musacchio RA (1997) Assessing, controlling, and assuring the quality of medical information on the Internet: Caveant lector et viewor—Let the reader and viewer beware. JAMA 277(15):1244–1245CrossRefPubMed
11.
Zurück zum Zitat Health on the Net Foundation. 2014. The HON code of conduct for medical and health web sites (HONcode). Available at: http://www.hon.ch. Accessed 02 June 2014. Health on the Net Foundation. 2014. The HON code of conduct for medical and health web sites (HONcode). Available at: http://​www.​hon.​ch. Accessed 02 June 2014.
12.
Zurück zum Zitat Charnock D, Shepperd S, Needham G, Gann R (1999) DISCERN: an instrument for judging the quality of written consumer health information on treatment choices. J Epidemiol Community Health 53(2):105–111CrossRefPubMedPubMedCentral Charnock D, Shepperd S, Needham G, Gann R (1999) DISCERN: an instrument for judging the quality of written consumer health information on treatment choices. J Epidemiol Community Health 53(2):105–111CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Leira-Feijoo, Y., Y. Ledesma-Ludi, J. M. Seoane-Romero, J. Blanco-Carrion, J. Seoane, and P. Varela-Centelles. 2014. Available web-based dental implants information for patients. How good is it? Clin Oral Implants Res. doi:10.1111/clr.12451. Leira-Feijoo, Y., Y. Ledesma-Ludi, J. M. Seoane-Romero, J. Blanco-Carrion, J. Seoane, and P. Varela-Centelles. 2014. Available web-based dental implants information for patients. How good is it? Clin Oral Implants Res. doi:10.​1111/​clr.​12451.
21.
Zurück zum Zitat Weiss BD (2003) Health literacy: a manual for clinicians. American Medical Association, American Medical Foundation, Chicago Weiss BD (2003) Health literacy: a manual for clinicians. American Medical Association, American Medical Foundation, Chicago
Metadaten
Titel
Prostate Cancer on the Web—Expedient Tool for Patients’ Decision-Making?
verfasst von
Hendrik Borgmann
Jan-Henning Wölm
Stefan Vallo
Rene Mager
Johannes Huber
Johannes Breyer
Johannes Salem
Stacy Loeb
Axel Haferkamp
Igor Tsaur
Publikationsdatum
04.08.2015
Verlag
Springer US
Erschienen in
Journal of Cancer Education / Ausgabe 1/2017
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-015-0891-3

Weitere Artikel der Ausgabe 1/2017

Journal of Cancer Education 1/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.